GlassScriptPhysician profile
Abdul Haseeb
NPI 1548754856
$1,694.35
in general payments reported to CMS, 2019-2025
18 companies · $740 in 2025
The $740 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $119 · 2023: $198 · 2024: $638 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,476 · Education: $99.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,476.04 |
| Education | $99.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $326.70 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $283.52 | 2022-2025 | Farxiga |
| Amgen INC. | $148.00 | 2024-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $142.07 | 2024-2025 | |
| Novo Nordisk INC | $135.32 | 2025 | Ozempic |
| Otsuka America Pharmaceutical, INC. | $129.40 | 2024-2025 | Jynarque |
| Akebia Therapeutics INC | $129.25 | 2025 | Vafseo |
| Travere Therapeutics, INC. | $101.35 | 2023-2025 | Filspari |
| Vifor Pharma, INC. | $66.86 | 2023-2025 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $51.21 | 2023-2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $41.17 | 2025 | Tarpeyo |
| Alnylam Pharmaceuticals INC. | $29.75 | 2024 | Amvuttra |
| Scpharmaceuticals INC. | $25.52 | 2025 | |
| Alexion Pharmaceuticals, INC. | $18.19 | 2024 | Ultomiris |
| Seqirus USA INC | $17.64 | 2023 | Flucelvax Quadrivalent |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Manufacturing, INC. | $16.94 | 2025 | |
| Lilly USA, LLC | $16.79 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $14.67 | 2024 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Haseeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.